London, UK, 1 October 2007, Curidium Medica plc, (LSE: CUR), the personalized medicine company focused on bringing the right drug to the right patient, today announced that the Company’s founder and scientific originator, Dr. Anne Bruinvels, Ph.D., who has been Chief Executive Officer (CEO) for the past six years, will assume the position of Chief Scientific Officer (CSO) of the Company, effective today. Gosse B. Bruinsma, M.D., the Company’s Executive Chairman, will assume the duties and responsibilities of the CEO. This move reflects Curidium’s increased focus on the commercialization and development of its diagnostic and therapeutic product portfolio since the successful identification of PsychINDx™, the Company’s diagnostic blood test that classifies patients with schizophrenia/bipolar disorder into different subgroups which may result in the improved treatment of these patients.
